Auris Huen, MD
Dermatology · Houston, TXNPI 1952696569
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,563 of the $45,062 with a category attached, or 67.8%. 12 manufacturers reported payments, led by Kyowa Kirin, Inc. at 59.9% of the total. Reporting peaked in 2019 at $16,255 and has fallen 96.0% since, to $647 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $763.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$27K
- Helsinn Therapeutics (U.S.), Inc.$9K
- Stemline Therapeutics Inc.$6K
- Blueprint Medicines Corporation$2K
- Adaptive Biotechnologies Corporation$357
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$350
- plus $464 from 6 others
Across 32 payments — averaging $8688.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$129K
- Pfizer$90K
- Innate Pharma, Inc$49K
- Eisai Inc.$7K
- Dr.reddy's Laboratories,inc.$4K
What the payments were for
- Consulting fees$30,56368%
- Speaking & faculty fees$6,84115%
- Travel & lodging$4,41410%
- Food & beverage$3,1757%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 27 | $26,970 |
| Helsinn Therapeutics (U.S.), Inc. | 7 | $8,931 |
| Stemline Therapeutics Inc. | 7 | $6,069 |
| Blueprint Medicines Corporation | 2 | $1,921 |
| Adaptive Biotechnologies Corporation | 4 | $357 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $350 |
| Vertex | 1 | $165 |
| Pfizer | 1 | $106 |
| Bausch Health US, LLC | 2 | $98 |
| Merck | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Seagen Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,062 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bexarotene | 35 | $89,627 |
| PegasysPeginterferon Alfa-2a | 20 | $76,151 |
| CibinqoAbrocitinib | 11 | $57,348 |
| Dupixent SyringeDupilumab | 13 | $48,647 |
| Acitretin | 22 | $4,450 |
| Clobetasol Propionate | 47 | $2,453 |
| Ketoconazole | 50 | $981 |
| Fluorouracil | 13 | $926 |
| Triamcinolone Acetonide | 61 | $825 |
| Imiquimod | 16 | $473 |
| Hydrocortisone | 28 | $379 |
| Gabapentin | 23 | $211 |
| Hydroxyzine Hcl | 15 | $206 |
| Mupirocin | 27 | $171 |
| Levothyroxine Sodium | 21 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerCibinqo | $106 | $57,34811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,098 dermatology providers in Texas.
Other dermatology in Houston
- Alpesh DesaiHouston$1.6M
- Geeta PatelHouston$575K
- Michael MigdenHouston$310K
- Catherine PapasakelariouHouston$289K
- Stephen MahoneyHouston$137K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.